Their evidence base is public: the STEP program studied semaglutide for weight management ( The New England Journal of Medicine , 2021), SURMOUNT studied tirzepatide for weight management (NEJM, 2022), and SURMOUNT-OSA examined tirzepatide in obstructive sleep apnea (NEJM, 2024)
It is not clear why the general public looks at these GLP-1 weight loss lawsuits as a monolith, of sorts, under the moniker of ozempic lawsuit. Strangely, some people who are taking mounjaro, for example, are searching google for a lawsuit against ozempic. These medications constitute a class of diabetes medication and weight loss prescriptions that are widely referenced as glucagon-like peptide-1 (GLP-1) receptor agonists
How Exercise and Sleep Affect GLP-1 Release Physical activity represents a powerful, evidence-based intervention for enhancing metabolic health
Importance of exercise Regular physical activity is equally crucial
How does Aqualyx work